Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and Ramsay ...

Novavax (NVAX) delivered earnings and revenue surprises of 32% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from ...

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo ...